Celsion Announces Jeffrey W. Church Reappointed to CFO

            Celsion Announces Jeffrey W. Church Reappointed to CFO

Company Completes Previously Announced Restructuring and Cash Conservation

PR Newswire

LAWRENCEVILLE, N.J., July 2, 2013

LAWRENCEVILLE, N.J., July 2, 2013 /PRNewswire/ --Celsion Corporation (Nasdaq:
CLSN) announced today that Jeffrey W. Church, Senior Vice President, will
resume the role of Chief Financial Officer, a position he held prior to his
promotion to Senior Vice President in July 2011. In this position he will
retain responsibility for corporate investor relations. Mr. Church joined
Celsion in July 2010 as Vice President and CFO. Mr. Church's re-appointment
will be effective immediately. Mr. Church has more than 30 years of
experience in financial management, the majority of which are as a Chief
Financial Officer for publicly traded life science companies.

This announcement follows the resignation of Gregory Weaver, the Company's
Chief Financial Officer who, after 7 years of service to Celsion, will be
pursuing other professional opportunities consistent with his extensive
experience in commercial and development stage companies. Mr. Weaver's
resignation, which is effective June 30, 2013, includes a transition plan
designed to ensure continuity of business operations.

Michael H. Tardugno, Celsion's President and Chief Executive Officer stated,
"Greg has made many important contributions to the Company as CFO and during
his six years of service as a Board Director. We thank him for his service
and wish him well in the pursuit of his new endeavors. It's also important to
note that the transition of CFO responsibilities is being made to a very
capable member of our senior management team, Jeff Church, and that this
restructuring is an integral part of the Company's cash conservation plans
announced earlier this year. We maintain our commitment to the efficient use
of our financial and human resources as we enter a pivotal time for the

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology. Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford. For more information on Celsion, visit
our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; the need for Celsion to evaluate its
future development plans; possible acquisitions or licenses of other
technologies, assets or businesses or the possible failure to make such
acquisitions or licenses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to
time in the Celsion 's periodic reports and prospectuses filed with the
Securities and Exchange Commission. Celsion assumes no obligation to update
or supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Senior Vice President

SOURCE Celsion Corporation

Website: http://www.celsion.com
Press spacebar to pause and continue. Press esc to stop.